TYK Medicines-B Shares Surge Over 5% as Qilu Pharma Secures Exclusive Rights for Lung Cancer Drug TY-9591

Deep News07-27

TYK Medicines-B (02410.HK) saw its share price jump more than 6% during intraday trading, currently up 5.39% to HKD 7.23, with a trading volume of HKD 17.57 million.

Qilu Pharmaceutical has secured the exclusive commercialisation rights for TYK Medicines-B's novel targeted lung cancer therapy, TY-9591. In addition, Qilu Pharmaceutical will make an equity investment in TYK Medicines-B. Through this partnership, TYK Medicines-B is entitled to receive HKD 700 million in share subscription proceeds and upfront cash payments, comprising HKD 400 million in equity investment and HKD 300 million in upfront fees. Furthermore, the company is eligible for regulatory approval and indication expansion milestone payments totalling up to HKD 2.06 billion.

According to public information, TY-9591 is a next-generation, highly selective, irreversible EGFR-TKI independently developed by TYK Medicines-B. It represents a differentiated and advantageous new lung cancer targeted drug in the domestic market. The new drug application for TY-9591 was accepted by the National Medical Products Administration in early 2026 and has been granted priority review status. It is currently in a critical stage of marketing review. Beyond monotherapy registration clinical trials, preparations for a registration trial involving a combination chemotherapy regimen have been initiated, signalling the approach of the commercialisation window.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128214014?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 13:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128214014","market":"other","top_or_hot":-1,"title":"TYK Medicines-B Shares Surge Over 5% as Qilu Pharma Secures Exclusive Rights for Lung Cancer Drug TY-9591","media":"Deep News","content":"<p><b>TYK Medicines-B</b> (<b>02410.HK</b>) saw its share price jump more than 6% during intraday trading, currently up 5.39% to HKD 7.23, with a trading volume of HKD 17.57 million.<br><br>\nQilu Pharmaceutical has secured the exclusive commercialisation rights for TYK Medicines-B's novel targeted lung cancer therapy, TY-9591. In addition, Qilu Pharmaceutical will make an equity investment in TYK Medicines-B. Through this partnership, TYK Medicines-B is entitled to receive HKD 700 million in share subscription proceeds and upfront cash payments, comprising HKD 400 million in equity investment and HKD 300 million in upfront fees. Furthermore, the company is eligible for regulatory approval and indication expansion milestone payments totalling up to HKD 2.06 billion.<br><br>\nAccording to public information, TY-9591 is a next-generation, highly selective, irreversible EGFR-TKI independently developed by TYK Medicines-B. It represents a differentiated and advantageous new lung cancer targeted drug in the domestic market. The new drug application for TY-9591 was accepted by the National Medical Products Administration in early 2026 and has been granted priority review status. It is currently in a critical stage of marketing review. Beyond monotherapy registration clinical trials, preparations for a registration trial involving a combination chemotherapy regimen have been initiated, signalling the approach of the commercialisation window.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK Medicines-B Shares Surge Over 5% as Qilu Pharma Secures Exclusive Rights for Lung Cancer Drug TY-9591</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK Medicines-B Shares Surge Over 5% as Qilu Pharma Secures Exclusive Rights for Lung Cancer Drug TY-9591\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-27 13:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>TYK Medicines-B</b> (<b>02410.HK</b>) saw its share price jump more than 6% during intraday trading, currently up 5.39% to HKD 7.23, with a trading volume of HKD 17.57 million.<br><br>\nQilu Pharmaceutical has secured the exclusive commercialisation rights for TYK Medicines-B's novel targeted lung cancer therapy, TY-9591. In addition, Qilu Pharmaceutical will make an equity investment in TYK Medicines-B. Through this partnership, TYK Medicines-B is entitled to receive HKD 700 million in share subscription proceeds and upfront cash payments, comprising HKD 400 million in equity investment and HKD 300 million in upfront fees. Furthermore, the company is eligible for regulatory approval and indication expansion milestone payments totalling up to HKD 2.06 billion.<br><br>\nAccording to public information, TY-9591 is a next-generation, highly selective, irreversible EGFR-TKI independently developed by TYK Medicines-B. It represents a differentiated and advantageous new lung cancer targeted drug in the domestic market. The new drug application for TY-9591 was accepted by the National Medical Products Administration in early 2026 and has been granted priority review status. It is currently in a critical stage of marketing review. Beyond monotherapy registration clinical trials, preparations for a registration trial involving a combination chemotherapy regimen have been initiated, signalling the approach of the commercialisation window.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1128214014","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128214014","pubTimestamp":1785129624,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"TYK Medicines-B (02410.HK) saw its share price jump more than 6% during intraday trading, currently up 5.39% to HKD 7.23, with a trading volume of HKD 17.57 million. Qilu Pharmaceutical has secured...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1191":"制药","BK1515":"抗疫概念","TY":"Tri-Continental Corp","02410":"同源康医药-B","BK1161":"生物科技","BK1574":"生物医药B类股","01477":"欧康维视生物-B","09939":"开拓药业-B"},"translate_title":"齐鲁制药获得肺癌药物TY-9591独家权利，TYK Medicines-B股价飙升逾5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02410":1,"TY":1,"01477":1,"09939":1},"content_text":"TYK Medicines-B (02410.HK) saw its share price jump more than 6% during intraday trading, currently up 5.39% to HKD 7.23, with a trading volume of HKD 17.57 million.\nQilu Pharmaceutical has secured the exclusive commercialisation rights for TYK Medicines-B's novel targeted lung cancer therapy, TY-9591. In addition, Qilu Pharmaceutical will make an equity investment in TYK Medicines-B. Through this partnership, TYK Medicines-B is entitled to receive HKD 700 million in share subscription proceeds and upfront cash payments, comprising HKD 400 million in equity investment and HKD 300 million in upfront fees. Furthermore, the company is eligible for regulatory approval and indication expansion milestone payments totalling up to HKD 2.06 billion.\nAccording to public information, TY-9591 is a next-generation, highly selective, irreversible EGFR-TKI independently developed by TYK Medicines-B. It represents a differentiated and advantageous new lung cancer targeted drug in the domestic market. The new drug application for TY-9591 was accepted by the National Medical Products Administration in early 2026 and has been granted priority review status. It is currently in a critical stage of marketing review. Beyond monotherapy registration clinical trials, preparations for a registration trial involving a combination chemotherapy regimen have been initiated, signalling the approach of the commercialisation window.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.0","shortVersion":"4.47.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128214014","isCrawlerRequest":true}